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Various drugs can cause prolongation of the QT interval in an
ECG, and in rare cases this is followed by the development of
potentially fatal Torsade de pointes (TdP) [1]. Since 2001,
reports to the drug authorities in Europe and the USA have
raised concerns that methadone may prolong the QT interval
and thereby cause fatal arrhythmias. QT prolongation induced
by methadone is dose-dependent. Patients treated for opioid
dependence with methadone often receive concomitant
medications for psychiatric disorders and infections (e.g.
HIV), which allows great potential for drug–drug interactions.
Described here is a case in which interruption of antiretroviral
treatment triggered TdP by elevating the level of methadone
in the patient’s blood.
A 53-year-old HIV-positive female patient presented in
December 2005 with a 2-month history of weakness, weight
loss (8 kg) and fatigue. She had contracted HIV in 1992.
Since July 2004 she had been on a combination antiretroviral
therapy (cART) consisting of tenofovir (245 mg once daily),
didanosine (250 mg once daily), fos-amprenavir (700 mg
twice daily) and lopinavir–ritonavir (400 mg/100 mg twice
daily). Other medications included methadone (75 mg twice
daily) and methylphenidate (20 mg twice daily) for opioid
dependence, and oxazepam (50 mg once daily) and
paroxetin (30 mg once daily) for an anxiety disorder.
Physical examination was unremarkable. Routine laboratory
studies revealed a slightly elevated alanine aminotransferase
level of 56 IU/l (normal <52 IU/l) and an increased lactate
value of 2.9 mmol/l (normal range 0.6–2.4 mmol/l). In 2001,
hepatitis C serology had been positive with an undetectable
level of HCV-RNA; at this presentation it was 472,000 IU/ml
and of genotype 1B. The HIV viral load was undetectable at
a CD4+ cell count of 212 cells per μl.
In January 2006, the patient was seen again because of
abdominal discomfort. Her lactate level had increased to
5.1 mmol/l. A presumptive diagnosis of symptomatic
hyperlactatemia was made and cART was discontinued.
Five days later she experienced symptomatic improvement
with resolution of her abdominal pain. The lactate level had
decreased to 3.3 mmol/l. Eight days after stopping cART,
the patient complained of palpitations and an ECG was
performed; this revealed a corrected QT interval of 654 ms
(normal <450 ms in women). Electrolyte blood levels were
low (potassium 3.2 mmol/l, phosphate 0.46 mmol/l,
magnesium 0.77 mmol/l). The patient was admitted to the
ICU on the same day and she developed TdP requiring
electromechanical conversion and intubation for 48 h
(Fig. 1). All oral medications were stopped and morphine
was substituted for methadone. Potassium levels were kept
above 5.0 mmol/l. Subsequent ECGs showed gradual
normalization of the corrected QT interval, reaching a
value of 420 ms after 4 days. After cART with tipranavir–
ritonavir, nevirapine, tenofovir and lamivudine was re-
sumed in February of 2006, the patient developed ascites
and had to be hospitalized again. Liver biopsy revealed a
fully cirrhotic liver. Despite discontinuation of cART and
the initiation of supportive therapy, the patient died of
complications related to liver failure.
Long QT syndrome (LQTS) is characterized by a
prolonged QT interval in the ECG as well as a patient’s
propensity to develop syncope and experience sudden
cardiac death due to the polymorphic ventricular arrhythmia
called TdP. The QT interval is predominantly determined
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by the duration of the action potential of ventricular cells.
Genetic or acquired factors that alter the balance between
inward and outward currents during the action potential
significantly prolong its duration. Most drugs known to
prolong the QT interval block a specific type of cardiac
potassium channel expressed by the human ether-a-go-go-
related gene involved in the repolarization phase of the cardiac
action potential; they thus lengthen the QT interval [2]. LQTS
has long been a well-known complication of anti-arrhythmic
drug treatment [3]. However, a growing list of non-anti-
arrhythmic drugs has been reported to cause LQTS.
Various other clinical factors have been identified that add
to the risk of developing TdP, which is the most severe form
of LQTS [4]. The most common is female gender (71% of
cases); others include heart diseases, hypokalemia, potential
drug interactions associated with the administration of two
or more drugs prolonging the QT interval and high drug
levels due to impaired metabolism or excessive dosage.
Methadone is a synthetic opioid frequently used in drug
maintenance programs for heroin addicts. This patient
population is characterized by high comorbidity, which
often leads to the administration of additional antiviral as
well as antibiotic drugs. Uncontrolled substance abuse is
frequent, as is antipsychotic treatment. Methadone and its
derivate levacetyl–methadone are the most potent inhibitors
of the delayed potassium ion current in human cells among
the opioid agonists, and both prolong the QT interval [5].
Methadone is mainly metabolised by the isoenzyme
CYP3A4 and, to a lesser extent, by the isoenzyme CYP2D6
of the hepatic cytochrome-P450-system [6]. These path-
ways are also utilized by numerous antibiotics, antivirals,
antihistamines, and antidepressants, all of which influence
the metabolism of methadone.
The association between methadone and TdP arrhythmias
was described for the first time in a case series of 17 patients in
2002 [7]. The mean dose of methadone at the time of TdP
tachycardia was very high (397±283 mg/day); six patients
had been prescribed a higher methadone dosage in the month
prior to the development of TdP. A study by Sticherling et al.
[8] reported five patients with TdP who were receiving
methadone in a drug maintenance program. All of the patients
had additional factors that influenced the QT time, namely,
the consumption of other QT-prolonging drugs, cocaine use,
taking of substances that increase the methadone level by
virtue of CYP3A4 inhibition (e.g. ciprofloxacin or cocaine),
or very low potassium levels. Our patient received only
150 mg of methadone daily and no new drugs had been
introduced in the month prior to the final presentation.
Three of the drugs taken by our patient (methadone,
paroxetine and methylphenidate) are known to prolong the
QT interval. The fact that she had been on the same dosage
of these three drugs for at least the preceding year without
any symptoms prompted us to seek additional factors that
might have triggered QT prolongation.
None of the antiretroviral drugs used by our patient are on
the list of drugs that can prolong the QT interval (www.
qtdrugs.org). Gil et al. [9] mention that among the HIV-
infected patients treated with methadone, drug interactions
have increased with the introduction of cART due to the
inhibitory and/or inducing effects on cytochrome P450. The
most frequently observed interaction is a decrease in
the levels of methadone circulating in patients taking non-
nucleoside reverse transcriptase inhibitors, and, less frequently,
protease inhibitors. These drugs are occasionally stopped
without any parallel decrease of the methadone doses. Two
studies have examined the clinical and pharmacokinetic
interactions between methadone and the protease inhibitors
lopinavir and ritonavir [10, 11]. Ritonavir has been shown to
inhibit CYP3A4, thereby slowing the pharmacokinetic
metabolism of lopinavir and producing lopinavir levels that
exceed the inhibitory concentrations for HIV [12]. Although
it would be expected that the simultaneous administration of
methadone with lopinavir–ritonavir would increase metha-
done concentrations, since it is mainly metabolized by
CYP3A4, the opposite effect was demonstrated in both
studies. In eight HIV-positive patients on methadone mainte-
nance therapy, a 36% reduction in the area under the plasma
concentration time curve was observed for methadone after
LPV/r was introduced, and no coincident symptoms of opioid
withdrawal were seen [10]. McCance-Katz et al. [11] showed
a similar pharmacokinetic effect in 15 healthy individuals
receiving LPV/r in addition to methadone-maintenance
therapy, i.e., significant reductions in the area under the
concentration time curve for methadone and a significant
increase in opiate withdrawal symptoms. The researchers
concluded that LPV/r leads to a net in vivo induction of
metabolic clearance of methadone involving CYP3A4 and
CYP2D6 and, possibly, intestinal glycoprotein P450.
We assume that the discontinuation of lopinavir–ritona-
vir in the case of our patient increased the level of
Fig. 1 Rhythm strip from the day of admission showing Torsade de pointes. QTc-time was 654 ms (corrected with the Bazett formula).
Hemodynamic instability necessitated multiple cardioversions
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methadone in the blood thus precipitating the QT prolon-
gation and near-fatal TdP. This is supported by the
unusually high methadone level of 2640 nmol/l detected
on the day of admission. Additional risk factors for the
development of TdP in this case were hypokalemia,
hypomagnesemia and female gender. Although a direct
effect of antiretroviral drugs on the QT interval has not
been demonstrated thus far, drug–drug interactions between
methadone and antiretroviral medications have to be taken
into consideration, not only when adding a new drug but
also when stopping drugs that have the potential to induce
drug metabolism. In the case described here, various
common risk factors for TdP were present, such as female
gender and electrolyte disturbances. Our patient was also
treated with various QT-prolonging drugs. In this case,
discontinuation of the protease inhibitor LPV/r led to an
increase in the concentration of methadone since there was
a lack of methadone metabolism induction.
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